<div id="readability-page-1"><p><span>Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report)</span>'s stock had its &#34;outperform&#34; rating reissued by equities researchers at Royal Bank of Canada in a research report issued on Tuesday, Benzinga reports. They presently have a $55.00 price target on the biopharmaceutical company's stock. Royal Bank of Canada's price target points to a potential upside of 33.24% from the stock's current price.</p><div><p><span></span><span>Get <strong>Xenon Pharmaceuticals</strong> alerts:</span></p></div><ul><li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li></ul><p>A number of other analysts have also recently issued reports on XENE. Cantor Fitzgerald reissued an &#34;overweight&#34; rating and issued a $65.00 price objective on shares of Xenon Pharmaceuticals in a research note on Friday, August 9th. Wedbush lowered their price objective on Xenon Pharmaceuticals from $50.00 to $49.00 and set an &#34;outperform&#34; rating on the stock in a research report on Friday, August 9th. Needham &amp; Company LLC cut their target price on Xenon Pharmaceuticals from $62.00 to $60.00 and set a &#34;buy&#34; rating for the company in a research report on Monday, August 12th. Finally, Citigroup lowered their price target on Xenon Pharmaceuticals from $62.00 to $60.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, May 10th. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, Xenon Pharmaceuticals presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $58.78.</p><p><b>Read Our Latest Stock Analysis on XENE</b></p><h2>Xenon Pharmaceuticals Trading Up 2.3 %</h2><p>Xenon Pharmaceuticals stock traded up $0.94 during trading on Tuesday, reaching $41.28. The company had a trading volume of 14,893 shares, compared to its average volume of 395,175. The firm has a market capitalization of $3.13 billion, a price-to-earnings ratio of -15.10 and a beta of 1.25. The firm's 50-day simple moving average is $40.29 and its 200 day simple moving average is $41.46. Xenon Pharmaceuticals has a 52 week low of $27.99 and a 52 week high of $50.99. </p><p>Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.05). During the same period in the previous year, the company earned ($0.72) earnings per share. On average, analysts predict that Xenon Pharmaceuticals will post -3.16 earnings per share for the current year. </p><h2>Institutional Investors Weigh In On Xenon Pharmaceuticals</h2><p>A number of hedge funds have recently bought and sold shares of the business. Parallel Advisors LLC raised its position in shares of Xenon Pharmaceuticals by 51.2% during the 4th quarter. Parallel Advisors LLC now owns 1,125 shares of the biopharmaceutical company's stock valued at $52,000 after buying an additional 381 shares in the last quarter. PNC Financial Services Group Inc. purchased a new position in shares of Xenon Pharmaceuticals in the 4th quarter worth approximately $91,000. 17 Capital Partners LLC bought a new position in shares of Xenon Pharmaceuticals during the 1st quarter valued at approximately $122,000. Quarry LP increased its position in shares of Xenon Pharmaceuticals by 207.7% during the 2nd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company's stock valued at $156,000 after purchasing an additional 2,700 shares during the last quarter. Finally, EntryPoint Capital LLC purchased a new stake in Xenon Pharmaceuticals during the 1st quarter valued at $195,000. Hedge funds and other institutional investors own 95.45% of the company's stock. </p><h2>Xenon Pharmaceuticals Company Profile</h2> (Get Free Report)<p>Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Xenon Pharmaceuticals</li><li>What is a support level?</li><li>Invest in Stability: Top 3 Blue-Chip Stocks for Turbulent Markets</li><li>What is the Dogs of the Dow Strategy? Overview and Examples</li><li>Joby Aviation Stock: Your Next High-Growth Opportunity</li><li>Trading Halts Explained</li><li>Don’t Count Out CrowdStrike Yet: Key Insights from Q2 Earnings</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ FREE Daily Profits Live Open House <span><span>(From Monument Traders Alliance)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDM5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDM5"/></p><h2>Should you invest $1,000 in Xenon Pharmaceuticals right now?</h2><p>Before you consider Xenon Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.</p><p>While Xenon Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

XENE

<p>Royal Bank of Canada reiterated its "outperform" rating for Xenon Pharmaceuticals (NASDAQ:XENE) with a price target indicating a potential upside of 33.24%. Other analysts have also weighed in, with ratings ranging from "buy" to "overweight". Currently, Xenon holds a consensus rating of "Moderate Buy" with an average target price of $9.78. Xenon's shares rose by 2.3% on the day of the report.</p>

Xenon Pharmaceuticals (NASDAQ:XENE) Rating Reiterated by Royal Bank of Canada